• +1-646-491-9876
    • +91-20-67278686

    Search

    Women Infertility - Pipeline Review, H1 2015

    Women Infertility - Pipeline Review, H1 2015

    • Report Code ID: RW0001172446
    • Category Pharmaceuticals
    • No. of Pages 214
    • Publication Month Jan-15
    • Publisher Name Global Markets Direct
    Women Infertility-Pipeline Review, H1 2015

    Summary

    Publisher's, 'Women Infertility-Pipeline Review, H1 2015', provides an overview of the Women Infertility's therapeutic pipeline.

    This report provides comprehensive information on the therapeutic development for Women Infertility, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Women Infertility and special features on late-stage and discontinued projects.

    Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Publisher's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

    The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

    Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

    Scope

    - The report provides a snapshot of the global therapeutic landscape of Women Infertility
    - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in the therapeutics development for Women Infertility and enlists all their major and minor projects
    - The report summarizes all the dormant and discontinued pipeline projects
    - A review of the Women Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - A detailed assessment of monotherapy and combination therapy pipeline projects
    - Coverage of the Women Infertility pipeline on the basis of target, MoA, route of administration and molecule type
    - Latest news and deals relating related to pipeline products

    Reasons to buy

    - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Identify and understand important and diverse types of therapeutics under development for Women Infertility
    - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
    - Devise corrective measures for pipeline projects by understanding Women Infertility pipeline depth and focus of Indication therapeutics
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
    Table of Contents
    Table of Contents 2
    List of Tables 6
    List of Figures 8
    Introduction 9
    Global Markets Direct Report Coverage 9
    Women Infertility Overview 10
    Therapeutics Development 11
    Pipeline Products for Women Infertility-Overview 11
    Pipeline Products for Women Infertility-Comparative Analysis 12
    Women Infertility-Therapeutics under Development by Companies 13
    Women Infertility-Therapeutics under Investigation by Universities/Institutes 18
    Women Infertility-Pipeline Products Glance 20
    Late Stage Products 20
    Clinical Stage Products 21
    Early Stage Products 22
    Unknown Stage Products 23
    Women Infertility-Products under Development by Companies 24
    Women Infertility-Products under Investigation by Universities/Institutes 29
    Women Infertility-Companies Involved in Therapeutics Development 30
    AbbVie Inc. 30
    Actavis plc 31
    Addex Therapeutics Ltd 32
    AlphaMab Co., Ltd 33
    APAvadis Biotechnologies Srl 34
    ASKA Pharmaceutical Co., Ltd. 35
    Astellas Pharma Inc. 36
    AstraZeneca PLC 37
    Bayer AG 38
    Crinetics Pharmaceuticals, Inc. 39
    Dong-A Socio Group 40
    Dongkook Pharmaceutical Co., Ltd. 41
    EffRx Pharmaceuticals S.A. 42
    ElexoPharm GmbH 43
    EndoCeutics, Inc. 44
    Euroscreen S.A. 45
    Evotec AG 46
    Ferring International Center S.A. 47
    Finox AG 48
    Forendo Pharma Oy 49
    GlaxoSmithKline plc 50
    Glycotope GmbH 51
    Isifer AB 52
    Kissei Pharmaceutical Co., Ltd. 53
    Lipicard Technologies Limited 54
    Merck & Co., Inc. 55
    Merck KGaA 56
    Neurocrine Biosciences, Inc. 57
    Nora Therapeutics, Inc. 58
    ObsEva SA 59
    Orphagen Pharmaceuticals, Inc. 60
    Pantec Biosolutions AG 61
    PharmaEssentia Corporation 62
    Philogen S.p.A. 63
    PlasmaTech Biopharmaceuticals, Inc. 64
    PregLem SA 65
    Reliance Life Sciences Pvt. Ltd. 66
    Repros Therapeutics Inc. 67
    SK Chemicals Co., Ltd. 68
    Takeda Pharmaceutical Company Limited 69
    Teva Pharmaceutical Industries Limited 70
    Trophogen, Inc. 71
    ValiRx Plc 72
    Zydus Cadila Healthcare Limited 73
    Women Infertility-Therapeutics Assessment 74
    Assessment by Monotherapy Products 74
    Assessment by Combination Products 75
    Assessment by Target 76
    Assessment by Mechanism of Action 79
    Assessment by Route of Administration 81
    Assessment by Molecule Type 83
    Drug Profiles 85
    (anastrozole + levonorgestrel)-Drug Profile 85
    acolbifene hydrochloride + GnRH agonist + prasterone-Drug Profile 86
    ADX-68692-Drug Profile 87
    AKP-501-Drug Profile 88
    ASP-1707-Drug Profile 89
    AZD-4901-Drug Profile 90
    barusiban-Drug Profile 91
    BAY-1026153-Drug Profile 92
    BAY-1128688-Drug Profile 93
    bentamapimod-Drug Profile 94
    Biosimilar 4 for Acute Myocardial Infarction and Infertility-Drug Profile 95
    Biosimilar 5 for Infertility-Drug Profile 96
    Biosimilar 6 for Infertility-Drug Profile 97
    Biosimilar 7 for Infertility and Oncology-Drug Profile 98
    choriogonadotropin alfa-Drug Profile 99
    choriogonadotropin alfa biosimilar-Drug Profile 100
    corifollitropin alfa-Drug Profile 101
    DR-2011-Drug Profile 103
    Drug to Inhibit C-Jun for Endometriosis-Drug Profile 104
    Drug to Target RERG for Endometriosis-Drug Profile 105
    Drugs for Endometriosis-Drug Profile 106
    Drugs for Endometriosis and Uterine Fibroids-Drug Profile 107
    elagolix sodium-Drug Profile 108
    Endole-Drug Profile 110
    epelsiban besylate-Drug Profile 111
    ESN-364-Drug Profile 113
    EVE-104-Drug Profile 114
    FE-999310-Drug Profile 115
    follitropin alfa-Drug Profile 116
    follitropin alfa-Drug Profile 117
    follitropin alfa (recombinant)-Drug Profile 118
    follitropin delta-Drug Profile 120
    FP-5677-Drug Profile 121
    FSH-GEX-Drug Profile 122
    goserelin biosimilar-Drug Profile 124
    Isifera-Drug Profile 125
    kisspeptin-Drug Profile 126
    KLH-2109-Drug Profile 127
    KN-015-Drug Profile 128
    LM-001-Drug Profile 129
    LM-002-Drug Profile 130
    LT-6121-Drug Profile 131
    menotropins-Drug Profile 132
    metformin hydrochloride-Drug Profile 133
    Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis-Drug Profile 134
    NCE-403-Drug Profile 135
    NT-100-Drug Profile 136
    OBE-001-Drug Profile 137
    Oral Fertility Drugs-Drug Profile 138
    PEG-FSH-Drug Profile 139
    Peptides for Cancer and Endometriosis-Drug Profile 140
    Peptides to Inhibit Aminopeptidase A for Cancer and Endometriosis-Drug Profile 141
    PGL-1001-Drug Profile 142
    PGL-2001-Drug Profile 143
    PGL-3001-Drug Profile 144
    progesterone nanoparticles-Drug Profile 145
    Progesterone Second Generation-Drug Profile 146
    Recombinant Protein for Endometriosis and Ovarian Hyperstimulation Syndrome-Drug Profile 147
    Recombinant Protein to Agonize Luteinizing Hormone for Infertility-Drug Profile 148
    relugolix-Drug Profile 149
    RTPR-013-Drug Profile 150
    Small Molecule to Agonize FSHR for Infertility-Drug Profile 151
    Small Molecule to Antagonize FSH Receptor for Women's Health-Drug Profile 152
    Small Molecules for Female Infertility-Drug Profile 153
    Small Molecules to Antagonize GnRH for Endometriosis, Uterine Fibroids, PCOS and Oncology-Drug Profile 154
    Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis-Drug Profile 155
    Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease-Drug Profile 156
    Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis-Drug Profile 157
    Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers-Drug Profile 158
    Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis-Drug Profile 159
    Small Molecules to Inhibit KISS-1R for Polycystic Ovarian Syndrome-Drug Profile 160
    Small Molecules to Inhibit Plasminogen Activator Inhibitor-1 for Thromboembolic Disease, PCOS and Alopecia-Drug Profile 161
    SR-16234-Drug Profile 162
    Synthetic Peptide for Metabolic Syndrome and Polycystic Ovarian Syndrome-Drug Profile 163
    Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology-Drug Profile 164
    telapristone acetate-Drug Profile 165
    Tetravil-Drug Profile 168
    TR-4401-Drug Profile 170
    triptorelin-Drug Profile 171
    triptorelin pamoate biosimilar-Drug Profile 172
    VAL-201-Drug Profile 173
    vilaprisan-Drug Profile 174
    VPE-001-Drug Profile 175
    Women Infertility-Recent Pipeline Updates 176
    Women Infertility-Dormant Projects 195
    Women Infertility-Discontinued Products 199
    Women Infertility-Product Development Milestones 201
    Featured News & Press Releases 201
    Appendix 207
    Methodology 207
    Coverage 207
    Secondary Research 207
    Primary Research 207
    Expert Panel Validation 207
    Contact Us 207
    Disclaimer 208

    List of Tables
    Number of Products under Development for Women Infertility, H1 2015 17
    Number of Products under Development for Women Infertility-Comparative Analysis, H1 2015 18
    Number of Products under Development by Companies, H1 2015 20
    Number of Products under Development by Companies, H1 2015 (Contd..1) 21
    Number of Products under Development by Companies, H1 2015 (Contd..2) 22
    Number of Products under Development by Companies, H1 2015 (Contd..3) 23
    Number of Products under Investigation by Universities/Institutes, H1 2015 25
    Comparative Analysis by Late Stage Development, H1 2015 26
    Comparative Analysis by Clinical Stage Development, H1 2015 27
    Comparative Analysis by Early Stage Development, H1 2015 28
    Comparative Analysis by Unknown Stage Development, H1 2015 29
    Products under Development by Companies, H1 2015 30
    Products under Development by Companies, H1 2015 (Contd..1) 31
    Products under Development by Companies, H1 2015 (Contd..2) 32
    Products under Development by Companies, H1 2015 (Contd..3) 33
    Products under Development by Companies, H1 2015 (Contd..4) 34
    Products under Investigation by Universities/Institutes, H1 2015 35
    Women Infertility-Pipeline by AbbVie Inc., H1 2015 36
    Women Infertility-Pipeline by Actavis plc, H1 2015 37
    Women Infertility-Pipeline by Addex Therapeutics Ltd, H1 2015 38
    Women Infertility-Pipeline by AlphaMab Co., Ltd, H1 2015 39
    Women Infertility-Pipeline by APAvadis Biotechnologies Srl, H1 2015 40
    Women Infertility-Pipeline by ASKA Pharmaceutical Co., Ltd., H1 2015 41
    Women Infertility-Pipeline by Astellas Pharma Inc., H1 2015 42
    Women Infertility-Pipeline by AstraZeneca PLC, H1 2015 43
    Women Infertility-Pipeline by Bayer AG, H1 2015 44
    Women Infertility-Pipeline by Crinetics Pharmaceuticals, Inc., H1 2015 45
    Women Infertility-Pipeline by Dong-A Socio Group, H1 2015 46
    Women Infertility-Pipeline by Dongkook Pharmaceutical Co., Ltd., H1 2015 47
    Women Infertility-Pipeline by EffRx Pharmaceuticals S.A., H1 2015 48
    Women Infertility-Pipeline by ElexoPharm GmbH, H1 2015 49
    Women Infertility-Pipeline by EndoCeutics, Inc., H1 2015 50
    Women Infertility-Pipeline by Euroscreen S.A., H1 2015 51
    Women Infertility-Pipeline by Evotec AG, H1 2015 52
    Women Infertility-Pipeline by Ferring International Center S.A., H1 2015 53
    Women Infertility-Pipeline by Finox AG, H1 2015 54
    Women Infertility-Pipeline by Forendo Pharma Oy, H1 2015 55
    Women Infertility-Pipeline by GlaxoSmithKline plc, H1 2015 56
    Women Infertility-Pipeline by Glycotope GmbH, H1 2015 57
    Women Infertility-Pipeline by Isifer AB, H1 2015 58
    Women Infertility-Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 59
    Women Infertility-Pipeline by Lipicard Technologies Limited, H1 2015 60
    Women Infertility-Pipeline by Merck & Co., Inc., H1 2015 61
    Women Infertility-Pipeline by Merck KGaA, H1 2015 62
    Women Infertility-Pipeline by Neurocrine Biosciences, Inc., H1 2015 63
    Women Infertility-Pipeline by Nora Therapeutics, Inc., H1 2015 64
    Women Infertility-Pipeline by ObsEva SA, H1 2015 65
    Women Infertility-Pipeline by Orphagen Pharmaceuticals, Inc., H1 2015 66
    Women Infertility-Pipeline by Pantec Biosolutions AG, H1 2015 67
    Women Infertility-Pipeline by PharmaEssentia Corporation, H1 2015 68
    Women Infertility-Pipeline by Philogen S.p.A., H1 2015 69
    Women Infertility-Pipeline by PlasmaTech Biopharmaceuticals, Inc., H1 2015 70
    Women Infertility-Pipeline by PregLem SA, H1 2015 71
    Women Infertility-Pipeline by Reliance Life Sciences Pvt. Ltd., H1 2015 72
    Women Infertility-Pipeline by Repros Therapeutics Inc., H1 2015 73
    Women Infertility-Pipeline by SK Chemicals Co., Ltd., H1 2015 74
    Women Infertility-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 75
    Women Infertility-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 76
    Women Infertility-Pipeline by Trophogen, Inc., H1 2015 77
    Women Infertility-Pipeline by ValiRx Plc, H1 2015 78
    Women Infertility-Pipeline by Zydus Cadila Healthcare Limited, H1 2015 79
    Assessment by Monotherapy Products, H1 2015 80
    Assessment by Combination Products, H1 2015 81
    Number of Products by Stage and Target, H1 2015 83
    Number of Products by Stage and Mechanism of Action, H1 2015 86
    Number of Products by Stage and Route of Administration, H1 2015 88
    Number of Products by Stage and Molecule Type, H1 2015 90
    Women Infertility Therapeutics-Recent Pipeline Updates, H1 2015 182
    Women Infertility-Dormant Projects, H1 2015 201
    Women Infertility-Dormant Projects (Contd..1), H1 2015 202
    Women Infertility-Dormant Projects (Contd..2), H1 2015 203
    Women Infertility-Dormant Projects (Contd..3), H1 2015 204
    Women Infertility-Discontinued Products, H1 2015 205
    Women Infertility-Discontinued Products (Contd..1), H1 2015 206

    List of Figures
    Number of Products under Development for Women Infertility, H1 2015 17
    Number of Products under Development for Women Infertility-Comparative Analysis, H1 2015 18
    Number of Products under Development by Companies, H1 2015 19
    Number of Products under Investigation by Universities/Institutes, H1 2015 24
    Comparative Analysis by Late Stage Development, H1 2015 26
    Comparative Analysis by Clinical Stage Development, H1 2015 27
    Comparative Analysis by Early Stage Products, H1 2015 28
    Assessment by Monotherapy Products, H1 2015 80
    Assessment by Combination Products, H1 2015 81
    Number of Products by Top 10 Targets, H1 2015 82
    Number of Products by Stage and Top 10 Targets, H1 2015 82
    Number of Products by Top 10 Mechanism of Actions, H1 2015 85
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 85
    Number of Products by Top 10 Routes of Administration, H1 2015 87
    Number of Products by Stage and Top 10 Routes of Administration, H1 2015 87
    Number of Products by Top 10 Molecule Types, H1 2015 89
    Number of Products by Stage and Top 10 Molecule Types, H1 2015 89
    AbbVie Inc.
    Actavis plc
    Addex Therapeutics Ltd
    AlphaMab Co., Ltd
    APAvadis Biotechnologies Srl
    ASKA Pharmaceutical Co., Ltd.
    Astellas Pharma Inc.
    AstraZeneca PLC
    Bayer AG
    Crinetics Pharmaceuticals, Inc.
    Dong-A Socio Group
    Dongkook Pharmaceutical Co., Ltd.
    EffRx Pharmaceuticals S.A.
    ElexoPharm GmbH
    EndoCeutics, Inc.
    Euroscreen S.A.
    Evotec AG
    Ferring International Center S.A.
    Finox AG
    Forendo Pharma Oy
    GlaxoSmithKline plc
    Glycotope GmbH
    Isifer AB
    Kissei Pharmaceutical Co., Ltd.
    Lipicard Technologies Limited
    Merck & Co., Inc.
    Merck KGaA
    Neurocrine Biosciences, Inc.
    Nora Therapeutics, Inc.
    ObsEva SA
    Orphagen Pharmaceuticals, Inc.
    Pantec Biosolutions AG
    PharmaEssentia Corporation
    Philogen S.p.A.
    PlasmaTech Biopharmaceuticals, Inc.
    PregLem SA
    Reliance Life Sciences Pvt. Ltd.
    Repros Therapeutics Inc.
    SK Chemicals Co., Ltd.
    Takeda Pharmaceutical Company Limited
    Teva Pharmaceutical Industries Limited
    Trophogen, Inc.
    ValiRx Plc
    Zydus Cadila Healthcare Limited

    Request for Sample

    Report Url https://www.reportsweb.com//women-infertility-pipeline-review-h1-2015&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//women-infertility-pipeline-review-h1-2015&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//women-infertility-pipeline-review-h1-2015&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments